What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Search
Nach Verein filtern
Read More
Iniciativas de Impacto
First.Cash.Expert: Обменник криптовалют онлайн
Криптовалютный рынок продолжает стремительно развиваться, привлекая всё больше пользователей,...
Von Sonnick84 Sonnick84 2025-10-10 11:02:10 0 0
Conteúdo Técnico
Neuromorphic Computing Market Growth Drivers Opportunities and Future Outlook
The Neuromorphic Computing Market Growth Drivers Opportunities and Future...
Von Akash Vibhute 2026-07-15 11:12:12 0 0
Lançamentos & Anúncios
Charting the Key Drivers Behind Unprecedented Security Operation Center Market Growth
The consistent and powerful expansion of the SOC market is not accidental but is propelled by a...
Von Grace Willson 2025-10-06 09:24:42 0 0
Oportunidade
Bahrain Construction Market Market Size and Forecast
Bahrain Construction Market Report Overview The Bahrain Construction Market report...
Von Vikas Hundekar 2026-03-12 11:48:29 0 0
Saúde & Bem Estar
Reinforced Surgical Gown Market to Reach US$ 3.4 Billion by 2034 at 7.53% CAGR
According to The Insight Partners, the global Reinforced Surgical Gown Market size is projected...
Von Terri Buckley 2026-10-28 13:34:46 0 0